Christopher Jewell
Chief Scientific Officer Cartesian Therapeutics
Seminars
Clinical Safety & Impact of RNA Cell Therapy in Patients with Myasthenia Gravis
9:30 am
- 10:00 am
- RNA cell therapy allows transient expression of chimeric antigen receptor in T cells, enabling therapies that do not require lymphodepletion and
eliminate risk of cancerous transformation - Expanding the potential of cell therapies to patients with autoimmunity, where the risk-benefit ratio is more stringent than in oncology
- Sharing our latest data from clinical trials using our autologous BCMA CAR-T product family to treat patients with autoimmunity
